Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.03% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.10B.
Undervalued
The company’s latest PE is -26.97, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.30M shares, decreasing 38.29% quarter-over-quarter.
Held by Larry Robbins
Star Investor Larry Robbins holds 1.93M shares of this stock.